NWBO : Summary for NORTHWEST BIOTHERA COM USD0.001 - Yahoo Finance

U.S. Markets closed

Northwest Biotherapeutics, Inc. (NWBO)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.40-0.03 (-7.06%)
At close: 3:59PM EST
People also watch
IMUCGALECLDXIDRATHLD
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.43
Open0.42
Bid0.00 x
Ask0.00 x
Day's Range0.39 - 0.42
52 Week Range0.32 - 2.50
Volume1,963,689
Avg. Volume1,853,398
Market Cap60.6M
Beta1.20
PE Ratio (TTM)-0.50
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 days ago

    FDA lifts hold on Northwest Bio’s brain cancer immunotherapy trial

    A clinical hold on phase 3 trials for a brain cancer immunotherapy candidate from Northwest Biotherapeutics Inc. was recently lifted by the U.S. Food and Drug Administration. The Bethesda-based company is working to develop products to stimulate the human immune system to reverse tumor growth and kill cancer cells and has several human clinical trials underway. The trial in question, DCVax-L, is for for glioblastoma multiforme brain cancer.

  • Investopedia13 days ago

    FDA Lifts Hold on Northwest Bio Cancer Drug Trial

    The FDA lifted an 18-month ban on Northwest Bio's cancer vaccine study.

  • PR Newswire14 days ago

    NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached

    BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company's Phase III trial of DCVax®-L for Glioblastoma multiforme ("GBM") brain cancer (the "Trial").  The Company announced that the partial clinical hold on the Trial has been lifted by the FDA, and that the Trial has accumulated a sufficient number of events toward the progression-free survival ("PFS") endpoint, but not yet for the overall survival ("OS") endpoint. The Company remains blinded to all Trial data, and is only receiving and reporting updates on a blinded basis.